D. Von Hoff - Concepedia

Author

D. Von Hoff

The University of Texas Health Science Center at San Antonio

Also Known As

D Von Hoff, D. VON HOFF, D. Von Hoff, D. von Hoff, Daniel Von Hoff, Joost Drenth, Von Hoff, D.

Publications

Citations

H-Index

Concepts

All Affiliations

The University of Texas Health Science Center at San Antonio Texas Oncology

About

D. Von Hoff is an author at The University of Texas Health Science Center at San Antonio specializing in medicine, oncology, and pharmacology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	8	8	855
2	Pharmacology	5	5	398
3	Pathology	2	2	181
4	Cell Biology	1	1	77
5	Immunology	1	1	49

D. Von Hoff

Publications

1.9K

Citations

H-Index

Page 1

	Year	Citations
Phase III Trial of Gemcitabine Plus Tipifarnib Compared With Gemcitabine Plus Placebo in Advanced Pancreatic Cancer Eric Van Cutsem, Helgi van de Velde, Petr Karásek, Journal of Clinical Oncology	2004	772
A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer Helmut Oettle, Donald Richards, Rajesh Ramanathan, Annals of Oncology UrologyOncologySurgical OncologyPancreatic CancerGastrointestinal Oncology	2005	304
A phase I trial of taxol given by a 6-hour intravenous infusion. T.D. Brown, Kathleen A. Havlin, Geoffrey R. Weiss, Journal of Clinical Oncology Pharmaceutical ScienceOncologyPhase Ii InvestigationPharmacologyClinical Trials	1991	182
Phase I Evaluation of ISIS 3521, an Antisense Oligodeoxynucleotide to Protein Kinase C-Alpha, in Patients With Advanced Cancer John Nemunaitis, Jon Holmlund, Maura A. Kraynak, Journal of Clinical Oncology	1999	172
DNA sequence amplification in human prostate cancer identified by chromosome microdissection: potential prognostic implications. C. van den Berg, Xin‐Yuan Guan, D. Von Hoff, PubMed Gene AmplificationUrologyGenitourinary CancerTumor HeterogeneityMedicine	1995	104
A phase I pharmacokinetic and pharmacodynamic study of AT7519, a cyclin-dependent kinase inhibitor in patients with refractory solid tumors Daruka Mahadevan, Ruth Plummer, Matthew Squires, Annals of Oncology Pharmacodynamic StudyOncologyMedicinePharmacotherapyRefractory Solid Tumors	2011	86
Effect of telomere and telomerase interactive agents on human tumor and normal cell lines. Sun Young Rha, Elżbieta Izbicka, R. A. Lawrence, PubMed Chemoprevention StrategyTelomerase ActivityPathologyCancer BiologyTumor Biology	2000	77
Mitoguazone therapy in patients with refractory or relapsed AIDS-related lymphoma: results from a multicenter phase II trial. A Levine, Anil Tulpule, D K Tessman, Journal of Clinical Oncology	1997	53
Phase I study of the novel Cdc2/CDK1 and AKT inhibitor terameprocol in patients with advanced leukemias Raoul Tibes, Kevin T. McDonagh, Lazaros J. Lekakis, Investigational New Drugs Hematological MalignancyAdvanced LeukemiasAkt Inhibitor TerameprocolMedicineImmunology	2014	49
A phase I and pharmacologic study of capecitabine and paclitaxel in breast cancer patients Miguel A. Villalona‐Calero, Joanne L. Blum, Stephen E. Jones, Annals of Oncology Breast OncologyOncologyBreast Cancer PatientsMedicineBreast Cancer	2001	42

Page 1